益气活血中药治疗慢性肾衰的机理研究
|
摘要
背景
慢性肾衰竭(CRF)为内科常见病之一,是各种肾脏疾病导致肾功能渐进性不可逆性减退,直至功能丧失所出的一系列症状和代谢紊乱所组成的临床综合征,其病情危重,死亡率高。
西医非透析治疗的目的主要是缓解慢性肾衰症状和延缓病程进展,主要措施包括消除CRF进展的可逆因素；治疗原发病,如高血压病、糖尿病肾病等；抗感染,水电解质平衡等；优质低蛋白饮食,加必需氨基酸或酮酸；保护肾脏功能、减轻蛋白尿的血管紧张素Ⅱ酶转化酶抑制剂的应用；调节脂质代谢和改善肾小球局部存在高凝状态。
中医中药治疗慢性肾衰以中药的单味药、单方、复方制剂及综合疗法,通过多环节、多层次、多途径综合治疗措施而达到缓解慢性肾衰症状,保护肾功能,延缓病程进展的目的。
多年的临床实践经验表明,慢性肾衰的治疗,采用中西医结合的综合治疗,特别是中药介入治疗后,在缓解慢性肾功能衰竭症状,保护残余肾功能、延缓早中期肾功能进展、推迟进入透析和肾移植时间等方面取得了明显疗效,提高了CRF患者的生存质量。益气活血中药三芪口服液在慢性肾脏病的治疗以及改善慢性肾衰的症状,延缓慢性肾衰的病程进展,保护肾功能方面积累了一定的经验。本研究从细胞黏附因子、炎症因子、细胞凋亡和T淋巴细胞亚群上,多角度、多靶点研究三芪口服液的影响,旨在探讨中药介入慢性肾衰治疗的肾功能保护作用以及三芪口服液保护肾功能的作用机理。
目的
通过临床和实验研究观察益气活血中药三芪口服液对慢性肾衰病人及对5／6肾切除慢性肾衰大鼠模型肾脏病理形态和功能的保护作用,从分子生物学、细胞凋亡以及淋巴细胞免疫方面,探讨益气活血中药三芪口服液延缓CRF进展的机理。
方法
临床研究：选择纳入标准的病例95例,分为3组,三芪口服液组34例,尿毒清组30例,三芪口服液+尿毒清组31例,每组患者均按就诊顺序随机进入治疗组及对照组。12周后观察慢性肾衰的症状积分、血红蛋白、红细胞压积、血小板计数、血清白蛋白、尿素、肌酐、血钾、血小板膜α颗粒蛋白(PS)的变化。
实验研究：选用SPF雄性SD大鼠102只。使用随机软件包PEMS3.1产生随机数字,按随机数字大小排序,等分为6组,每组17只,造模过程死亡24只,实际78只,空白组13只,模型对照组13只、三芪口服液高剂量组(TMH组)13只、三芪口服液中剂量组(TMM组)13只,三芪口服液低剂量组(TML组)13只、包醛氧淀粉组13只。建立大鼠5／6肾切除慢性肾衰的模型,造模成功后用三芪口服液口服进行干预治疗,12周后分别观察各组大鼠一般情况、肾功能、红细胞压积、血小板计数和血小板膜α颗粒蛋白的变化,以及光镜下肾小球组织的改变,细胞凋亡的分析,TNF-α、TGFβ1、PGDFBB以及CD4、CD8和CD68的变化。
结果
临床实验研究方面：治疗前后三芪口服液组中医症状积分比较,差异有统计学意义(P<0.05)。提示三芪口服液有改善慢性肾衰症状的作用。提示三芪口服液与尿毒清合用能明显提高临床治疗有效率,治疗有效率96.8%。三芪口服液能降低血尿素水平,提高血清白蛋白水平并可以下调PS的表达。治疗前后比较,差异有统计学意义(P<0.05)。口服三芪口服液,患者依从性较好,未发生出血及不良事件。
基础实验研究：血生化方面,三芪口服液各剂量组均可降低造模大鼠的血尿素和血肌酐水平,中剂量可以提高造模大鼠的血红蛋白压积,高、中剂量可以降低造模大鼠的血小板,治疗前后比较有统计学意义(P<0.05)。细胞黏附因子方面,三芪口服液中、低剂量可以下调PS的表达。治疗前后比较有统计学意义(P<0.05)。在残肾病理组织学方面,三芪口服液可以使增大的肾小球面积明显缩小,可以减轻肾小管损伤程度。与包醛氧淀粉组比较,差异有统计学意义(P<0.05)。细胞因子研究方面,经三芪口服液治疗后,无论高、中、低剂量组,大鼠血清TNF-α、FPDGBB以及残肾组织的TGFβ1、FPDGBB水平均明显降低,与模型组比较,差异有统计学意义(P<0.05)。细胞凋亡方面,经三芪口服液治疗后,5／6肾切除大鼠慢性肾衰肾脏细胞凋亡率明显降低,与包醛氧淀粉酶组比较,差异有统计学意义(P<0.05)。淋巴细胞免疫方面,三芪口服液中、低剂量组可以显著上调CD4水平,使CD4／CD8比值明显上升,CD68水平下调,与包醛氧淀粉组比较,差异有统计学意义(P<0.05)。
结论
1.三芪口服液能改善慢性肾衰患者中医症状积分,提高临床治疗有效率。
2.三芪口服液能提高慢性肾衰患者血清白蛋白水平,改善患者营养状态。
3.三芪口服液能够通过下调慢性肾衰患者血浆PS的表达,改善患者的瘀血状态,从而改善患者肾小球微循环,此可能是保护肾功能的机制之一。
4.三芪口服液能够降低5／6肾切除CRF模型大鼠的Scr水平,提高红细胞压积,改善机体整体状态。
5.三芪口服液能减轻5／6肾切除大鼠的肾脏病理损害,使增大的肾小球面积明显减小,肾小管损伤程度明显减轻,对残肾组织的形态有保护作用,此可能是保护肾功能的作用机制之一。
6.三芪口服液能抑制TNF-α、PDGFBB和TGFβ1的表达,减少肾小管损害,减少细胞增生,以此达到保护肾功能的目的。
7.肾脏实质细胞的凋亡参与肾脏疾病的进展过程,可能是促进慢性肾硬化发生、发展的因素之一,三芪口服液能使5／6肾切除CRF模型大鼠凋亡细胞明显减少,从而抑制细胞凋亡参与的肾脏损伤,延缓慢性肾衰的进展。
8.三芪口服液保护肾功能的机制可能与调整CD4和CD8的比例失调,调整异常的机体免疫紊乱和状态,减少了各种免疫受损的诱因有关,可能是其延缓CRF进展的机制之一。
Background
Chronic Renal Failure (CRF), a common disease, is a clinical syndrome of a variety of kidney diseases which lead to progressive irreversible kidney function decline until a loss of function through a series of symptom and metabolic disorders. Chronic renal failure is critical and with high mortality.
The purpose of Western non-dialysis treatments for chronic renal failure is to relieve symptoms and delay progression. The main measures include slowing the progress of CRF reversible factors; treating of primary diseases such as hypertension and diabetic nephropathy; resisting of infections; maintaining a balance of water and electrolyte; delivering high quality and low protein diets, plus essential amino acids or keto acids; applying angiotensin converting enzyme inhibitor enzyme to reduce proteinuria and protect kidney function; regulating lipid metabolism; and improving the local presence of a glomerular hypercoagulable state.
The Chinese medicine treatment for chronic renal failure in a single herb compound or combination therapy, utilizing multi-link, multi-level, multi-channel integrated measures to ease symptoms of chronic renal failure and protect renal function, thereby delaying progression.
Years of clinical experience have shown that the treatment of chronic renal failure with a comprehensive application of Chinese and western medicines, especially after interventional treatment with Chinese medicine, alleviates symptoms of chronic renal failure, protects residual renal function and delays renal function decline as soon as early and mid-term progress. The comprehensive combination theraby delays dialysis and renal transplantation, resulting in improved quality of life for patients with CRF.
Evidence supports that the Chinese medicine, Sanqi (radix astragali seu hedysari and Radix notoginseng)Oral Liquid, which has the effect of supplementing Qi and activating blood circulation, improves symptoms of chronic renal failure, delays the progression of chronic renal failure and protects renal function.
In this study, cell adhesion factors, inflammatory factors, apoptosis and T cell subsets were observed. The multi-angle, multi-target effects of Sanqi Oral Liquid,a Chinese medicine, were observed after interventional treatment of renal function with Sanqi Oral Liquid.
Purpose
Clinical changes were observed in Chronic renal failure patients using the Sanqi oral liquid. Experimental study of Chinese medicine Sanqi Oral Liquid was based on previous studies utilizing chronic renal failure rats in a 5/6 rephrectomy pathology model to ascertain the protective effect on kidney morphology and function to simulate chronic renal failure in patients.Using molecular biology, apoptosis, and lymphocyte levels, the effectiveness of Sanqi Chinese medicines Oral Liquid supplementing Qi and activating blood circulation in delaying the progress of CRF mechanism was studied.
Methods
Clinical Trials:95 patients were randomly divided into three groups:Sanqi groups, thirty-four pat ients received Sanqi Oral Liquid; Thirty patients were placed in the Niaoduqing group; Thirty-one patients received Sanqi Oral Liquid +Niaoduqing.Patients were separated into the treatment groups and control groups by visits, randomly. After 12 weeks, symptom scores, hemobl obin levels, hematorits, platelet counts, serum albumin, urea, creatine and potassium levels, as well as plateletαgranule membrane prote in changes were evaluated.
Exper imental studies:78 SPF male SD rats, using the random number generated package PEMS 3.1 subjects were divided into 6 groups:control group-13, model control group-13, Sanqi Oral Liquid high-dose group (TMH) group-13, Sanqi Oral medium dose group (TMM) group-13, Sanqi Oral Liquid low-dose group (TML) group-13, including coated al dehyde oxystarch group-13. Rats in 5/6 nephrectomy model of chronic renal failure received Sanqi Oral Liquid interventional treatment. Then,12 weeks later the rats were observed in the general situation,their kidney function, hematocrit, platelet count and plateletαgranule membrane protein changes were registered. Pathologica! changes in glomerular state were studied under light microscope. Apoptosis analysis was conducted. TNF-α,TGFβ1,PGDFBB, and CD4, CD8 and CD68 changes were observed.
Results
Clinical Trials:For the Sanqi Oral Liquid groups-a total efficiency of 82.4%; Sanq i Oral Liquid+Niaoduqing group-total efficiency of 96.8%. Compared to the Niaoduqing group, the differences were statistically significant (P<0.05). The Sanqi Oral Liquid group demonstrated significantly higher hematocrits and serum albumin and lower blood urea after treatment, compared to the Niaoduqing group (P<0.05). For the Sanqi Oral Liquid group before and after therapy, platelet a granule membrane protein (PS) decreased and the difference was statistically significant (P<0.05).
Experimental Studies:In the Sanqi Oral Liquid group, the blood urea and serum creatinine decrease after treatment was statistically significant (P<0.05). The Sanqi Oral Liquid middle-dose (TMM) and low-dose (TML) PS group had a statistically significant low expression after treatment (P<0.05). In residual glomerular morphology, the Sanqi Oral Liquid treatment groups significantly reduced the increased glomerular area, tubularinjury was mild.Also in the coated aldehyde oxystarch group the difference was significance (P<0.05). In cytokine research, the Sanqi Oral Liquid treatment group, regardless of high, medium or low dosage decreased the expression level of TGFβ1, compared with the coated aldehyde oxystarch group, the difference was significant (P<0.05).Sanqi Oral Liquid in the middle dose group significantly reduced the increased in apoptosis,compared with the coated aldehyde oxystarch group, the difference was statistically significant (P<0.05).Sanqi Oral Liquid in the middle and low dose group significantly raised CD4 levels,CD4/CD8 ratio also significantly increased compared with the coated aldehyde oxystarch group, the difference was significant (P<0.05).
Conclusions
1. Sanqi Oral Liquid can improve clinical symptoms in patients with chronic renal failure points, improve clinical efficiency.
2. Sanqi Oral Liquid can increase the level of serum albumin in chronic renal failure and improve nutritional status of patients.
3. Sanqi Oral Liquid can. decreases the blood expression lever of PS, improving the patient's blood stasis state, thereby protecting renal function.
4.Sanqi Oral Liquid can reduced the 5/6 nephrectomized CRF rats Scr, increase the hematocr its and improve the body statue, thereby delaying the progress of renal function decline.
5. Sanqi Oral Liquid can improve the 5/6 nephrectomy rats'renal pathological changes and provide residual renal protective effects.
6. Sanqi Oral Liquid can inhibit TNF-α,PGDFBB and TGFβ1 expression to renal hypertrophy,glomerular hyperfiltration state, etc.at different levels of mitigation, in order to achieve protection of renal function.
7.Sanqi Oral Liquid may significantly inhibit renal parenchymal cell apoptosis involved in the progression of renal disease and inhibit chronic renal sclerosis in 5/6 nephrectomy CRF rats.
8.Sanqi Oral Liquid's protective effects on renal function may be related to adjustment of the ratio of CD4 and CD8 disorders, reducing adjustment disorders and immune abnormalities, resulting in a reduction of a variety of immune impairments and slowing the progress of CRF.
慢性肾衰竭(CRF)为内科常见病之一,是各种肾脏疾病导致肾功能渐进性不可逆性减退,直至功能丧失所出的一系列症状和代谢紊乱所组成的临床综合征,其病情危重,死亡率高。
西医非透析治疗的目的主要是缓解慢性肾衰症状和延缓病程进展,主要措施包括消除CRF进展的可逆因素；治疗原发病,如高血压病、糖尿病肾病等；抗感染,水电解质平衡等；优质低蛋白饮食,加必需氨基酸或酮酸；保护肾脏功能、减轻蛋白尿的血管紧张素Ⅱ酶转化酶抑制剂的应用；调节脂质代谢和改善肾小球局部存在高凝状态。
中医中药治疗慢性肾衰以中药的单味药、单方、复方制剂及综合疗法,通过多环节、多层次、多途径综合治疗措施而达到缓解慢性肾衰症状,保护肾功能,延缓病程进展的目的。
多年的临床实践经验表明,慢性肾衰的治疗,采用中西医结合的综合治疗,特别是中药介入治疗后,在缓解慢性肾功能衰竭症状,保护残余肾功能、延缓早中期肾功能进展、推迟进入透析和肾移植时间等方面取得了明显疗效,提高了CRF患者的生存质量。益气活血中药三芪口服液在慢性肾脏病的治疗以及改善慢性肾衰的症状,延缓慢性肾衰的病程进展,保护肾功能方面积累了一定的经验。本研究从细胞黏附因子、炎症因子、细胞凋亡和T淋巴细胞亚群上,多角度、多靶点研究三芪口服液的影响,旨在探讨中药介入慢性肾衰治疗的肾功能保护作用以及三芪口服液保护肾功能的作用机理。
目的
通过临床和实验研究观察益气活血中药三芪口服液对慢性肾衰病人及对5／6肾切除慢性肾衰大鼠模型肾脏病理形态和功能的保护作用,从分子生物学、细胞凋亡以及淋巴细胞免疫方面,探讨益气活血中药三芪口服液延缓CRF进展的机理。
方法
临床研究：选择纳入标准的病例95例,分为3组,三芪口服液组34例,尿毒清组30例,三芪口服液+尿毒清组31例,每组患者均按就诊顺序随机进入治疗组及对照组。12周后观察慢性肾衰的症状积分、血红蛋白、红细胞压积、血小板计数、血清白蛋白、尿素、肌酐、血钾、血小板膜α颗粒蛋白(PS)的变化。
实验研究：选用SPF雄性SD大鼠102只。使用随机软件包PEMS3.1产生随机数字,按随机数字大小排序,等分为6组,每组17只,造模过程死亡24只,实际78只,空白组13只,模型对照组13只、三芪口服液高剂量组(TMH组)13只、三芪口服液中剂量组(TMM组)13只,三芪口服液低剂量组(TML组)13只、包醛氧淀粉组13只。建立大鼠5／6肾切除慢性肾衰的模型,造模成功后用三芪口服液口服进行干预治疗,12周后分别观察各组大鼠一般情况、肾功能、红细胞压积、血小板计数和血小板膜α颗粒蛋白的变化,以及光镜下肾小球组织的改变,细胞凋亡的分析,TNF-α、TGFβ1、PGDFBB以及CD4、CD8和CD68的变化。
结果
临床实验研究方面：治疗前后三芪口服液组中医症状积分比较,差异有统计学意义(P<0.05)。提示三芪口服液有改善慢性肾衰症状的作用。提示三芪口服液与尿毒清合用能明显提高临床治疗有效率,治疗有效率96.8%。三芪口服液能降低血尿素水平,提高血清白蛋白水平并可以下调PS的表达。治疗前后比较,差异有统计学意义(P<0.05)。口服三芪口服液,患者依从性较好,未发生出血及不良事件。
基础实验研究：血生化方面,三芪口服液各剂量组均可降低造模大鼠的血尿素和血肌酐水平,中剂量可以提高造模大鼠的血红蛋白压积,高、中剂量可以降低造模大鼠的血小板,治疗前后比较有统计学意义(P<0.05)。细胞黏附因子方面,三芪口服液中、低剂量可以下调PS的表达。治疗前后比较有统计学意义(P<0.05)。在残肾病理组织学方面,三芪口服液可以使增大的肾小球面积明显缩小,可以减轻肾小管损伤程度。与包醛氧淀粉组比较,差异有统计学意义(P<0.05)。细胞因子研究方面,经三芪口服液治疗后,无论高、中、低剂量组,大鼠血清TNF-α、FPDGBB以及残肾组织的TGFβ1、FPDGBB水平均明显降低,与模型组比较,差异有统计学意义(P<0.05)。细胞凋亡方面,经三芪口服液治疗后,5／6肾切除大鼠慢性肾衰肾脏细胞凋亡率明显降低,与包醛氧淀粉酶组比较,差异有统计学意义(P<0.05)。淋巴细胞免疫方面,三芪口服液中、低剂量组可以显著上调CD4水平,使CD4／CD8比值明显上升,CD68水平下调,与包醛氧淀粉组比较,差异有统计学意义(P<0.05)。
结论
1.三芪口服液能改善慢性肾衰患者中医症状积分,提高临床治疗有效率。
2.三芪口服液能提高慢性肾衰患者血清白蛋白水平,改善患者营养状态。
3.三芪口服液能够通过下调慢性肾衰患者血浆PS的表达,改善患者的瘀血状态,从而改善患者肾小球微循环,此可能是保护肾功能的机制之一。
4.三芪口服液能够降低5／6肾切除CRF模型大鼠的Scr水平,提高红细胞压积,改善机体整体状态。
5.三芪口服液能减轻5／6肾切除大鼠的肾脏病理损害,使增大的肾小球面积明显减小,肾小管损伤程度明显减轻,对残肾组织的形态有保护作用,此可能是保护肾功能的作用机制之一。
6.三芪口服液能抑制TNF-α、PDGFBB和TGFβ1的表达,减少肾小管损害,减少细胞增生,以此达到保护肾功能的目的。
7.肾脏实质细胞的凋亡参与肾脏疾病的进展过程,可能是促进慢性肾硬化发生、发展的因素之一,三芪口服液能使5／6肾切除CRF模型大鼠凋亡细胞明显减少,从而抑制细胞凋亡参与的肾脏损伤,延缓慢性肾衰的进展。
8.三芪口服液保护肾功能的机制可能与调整CD4和CD8的比例失调,调整异常的机体免疫紊乱和状态,减少了各种免疫受损的诱因有关,可能是其延缓CRF进展的机制之一。
Background
Chronic Renal Failure (CRF), a common disease, is a clinical syndrome of a variety of kidney diseases which lead to progressive irreversible kidney function decline until a loss of function through a series of symptom and metabolic disorders. Chronic renal failure is critical and with high mortality.
The purpose of Western non-dialysis treatments for chronic renal failure is to relieve symptoms and delay progression. The main measures include slowing the progress of CRF reversible factors; treating of primary diseases such as hypertension and diabetic nephropathy; resisting of infections; maintaining a balance of water and electrolyte; delivering high quality and low protein diets, plus essential amino acids or keto acids; applying angiotensin converting enzyme inhibitor enzyme to reduce proteinuria and protect kidney function; regulating lipid metabolism; and improving the local presence of a glomerular hypercoagulable state.
The Chinese medicine treatment for chronic renal failure in a single herb compound or combination therapy, utilizing multi-link, multi-level, multi-channel integrated measures to ease symptoms of chronic renal failure and protect renal function, thereby delaying progression.
Years of clinical experience have shown that the treatment of chronic renal failure with a comprehensive application of Chinese and western medicines, especially after interventional treatment with Chinese medicine, alleviates symptoms of chronic renal failure, protects residual renal function and delays renal function decline as soon as early and mid-term progress. The comprehensive combination theraby delays dialysis and renal transplantation, resulting in improved quality of life for patients with CRF.
Evidence supports that the Chinese medicine, Sanqi (radix astragali seu hedysari and Radix notoginseng)Oral Liquid, which has the effect of supplementing Qi and activating blood circulation, improves symptoms of chronic renal failure, delays the progression of chronic renal failure and protects renal function.
In this study, cell adhesion factors, inflammatory factors, apoptosis and T cell subsets were observed. The multi-angle, multi-target effects of Sanqi Oral Liquid,a Chinese medicine, were observed after interventional treatment of renal function with Sanqi Oral Liquid.
Purpose
Clinical changes were observed in Chronic renal failure patients using the Sanqi oral liquid. Experimental study of Chinese medicine Sanqi Oral Liquid was based on previous studies utilizing chronic renal failure rats in a 5/6 rephrectomy pathology model to ascertain the protective effect on kidney morphology and function to simulate chronic renal failure in patients.Using molecular biology, apoptosis, and lymphocyte levels, the effectiveness of Sanqi Chinese medicines Oral Liquid supplementing Qi and activating blood circulation in delaying the progress of CRF mechanism was studied.
Methods
Clinical Trials:95 patients were randomly divided into three groups:Sanqi groups, thirty-four pat ients received Sanqi Oral Liquid; Thirty patients were placed in the Niaoduqing group; Thirty-one patients received Sanqi Oral Liquid +Niaoduqing.Patients were separated into the treatment groups and control groups by visits, randomly. After 12 weeks, symptom scores, hemobl obin levels, hematorits, platelet counts, serum albumin, urea, creatine and potassium levels, as well as plateletαgranule membrane prote in changes were evaluated.
Exper imental studies:78 SPF male SD rats, using the random number generated package PEMS 3.1 subjects were divided into 6 groups:control group-13, model control group-13, Sanqi Oral Liquid high-dose group (TMH) group-13, Sanqi Oral medium dose group (TMM) group-13, Sanqi Oral Liquid low-dose group (TML) group-13, including coated al dehyde oxystarch group-13. Rats in 5/6 nephrectomy model of chronic renal failure received Sanqi Oral Liquid interventional treatment. Then,12 weeks later the rats were observed in the general situation,their kidney function, hematocrit, platelet count and plateletαgranule membrane protein changes were registered. Pathologica! changes in glomerular state were studied under light microscope. Apoptosis analysis was conducted. TNF-α,TGFβ1,PGDFBB, and CD4, CD8 and CD68 changes were observed.
Results
Clinical Trials:For the Sanqi Oral Liquid groups-a total efficiency of 82.4%; Sanq i Oral Liquid+Niaoduqing group-total efficiency of 96.8%. Compared to the Niaoduqing group, the differences were statistically significant (P<0.05). The Sanqi Oral Liquid group demonstrated significantly higher hematocrits and serum albumin and lower blood urea after treatment, compared to the Niaoduqing group (P<0.05). For the Sanqi Oral Liquid group before and after therapy, platelet a granule membrane protein (PS) decreased and the difference was statistically significant (P<0.05).
Experimental Studies:In the Sanqi Oral Liquid group, the blood urea and serum creatinine decrease after treatment was statistically significant (P<0.05). The Sanqi Oral Liquid middle-dose (TMM) and low-dose (TML) PS group had a statistically significant low expression after treatment (P<0.05). In residual glomerular morphology, the Sanqi Oral Liquid treatment groups significantly reduced the increased glomerular area, tubularinjury was mild.Also in the coated aldehyde oxystarch group the difference was significance (P<0.05). In cytokine research, the Sanqi Oral Liquid treatment group, regardless of high, medium or low dosage decreased the expression level of TGFβ1, compared with the coated aldehyde oxystarch group, the difference was significant (P<0.05).Sanqi Oral Liquid in the middle dose group significantly reduced the increased in apoptosis,compared with the coated aldehyde oxystarch group, the difference was statistically significant (P<0.05).Sanqi Oral Liquid in the middle and low dose group significantly raised CD4 levels,CD4/CD8 ratio also significantly increased compared with the coated aldehyde oxystarch group, the difference was significant (P<0.05).
Conclusions
1. Sanqi Oral Liquid can improve clinical symptoms in patients with chronic renal failure points, improve clinical efficiency.
2. Sanqi Oral Liquid can increase the level of serum albumin in chronic renal failure and improve nutritional status of patients.
3. Sanqi Oral Liquid can. decreases the blood expression lever of PS, improving the patient's blood stasis state, thereby protecting renal function.
4.Sanqi Oral Liquid can reduced the 5/6 nephrectomized CRF rats Scr, increase the hematocr its and improve the body statue, thereby delaying the progress of renal function decline.
5. Sanqi Oral Liquid can improve the 5/6 nephrectomy rats'renal pathological changes and provide residual renal protective effects.
6. Sanqi Oral Liquid can inhibit TNF-α,PGDFBB and TGFβ1 expression to renal hypertrophy,glomerular hyperfiltration state, etc.at different levels of mitigation, in order to achieve protection of renal function.
7.Sanqi Oral Liquid may significantly inhibit renal parenchymal cell apoptosis involved in the progression of renal disease and inhibit chronic renal sclerosis in 5/6 nephrectomy CRF rats.
8.Sanqi Oral Liquid's protective effects on renal function may be related to adjustment of the ratio of CD4 and CD8 disorders, reducing adjustment disorders and immune abnormalities, resulting in a reduction of a variety of immune impairments and slowing the progress of CRF.
引文
[1]黎磊石,刘志红.中国肾脏病学[M].北京：人民军医出版社,2008：1269.
[2]陈孝文,梁东,刘华锋,主编.慢性肾衰竭[M].北京：中国医药科技出版社,2006：25,148.
[3]Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population:Third National Health and Nutrition Examination Survey. Am J Kidney Dis,2003; 41(1): 1-12.
[4]张路霞,左力,徐国宾,等.北京市石景山地区中老年人群中慢性肾脏病的流行病学研究.中华肾脏病杂志,2006；22(2)：67-71.
[5]Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcomes. Kidney Int,2004; 66(4):1310-1314.
[6]Lysaght MJ. Maintenance dialysis population dynamics:current trends and long-term implications.J Am Soc Nephrol,2002; 13 Suppl 1:S37-40.
[7]Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection:frustration and promises. Kidney Int,2003; 64(6):1947-1955.
[8]Hamoma K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis,2002; 39(4):695-705.
[9]杨霓芝,王立新,林启展,等.通脉口服液治疗慢性肾炎气虚血瘀证32例疗效观察.新中医,2003；35(1)：19-21.
[10]王立新,杨霓芝,包昆,等.通脉口服液对系膜增殖性肾炎大鼠血液流变学的影响.中医药研究,2001；17(1)：42-43.
[11]杨霓芝,包昆,王立新,等通脉口服液对大鼠慢性肾炎“气虚血瘀证”模型的组织形态学影响.中国中医药信息杂志,2001；8(3)：31-33.
[12],杨霓芝,钟丹,赵代鑫,等.通脉口服液对肾小球系膜细胞增殖及白细胞介素β1、白细胞介素10表达的影响.中国西医结合肾病杂志,2007；8(8)：444-447.
[13]钟丹,杨霓芝,赵代鑫,等.中药复方“通脉口服液”对肾小球系膜细胞增殖及分泌IL-1β的影响.时珍国医国药,2008；19(1)：4-6.
[14]杨霓芝,包昆,王立新,等.通脉口服液对慢性肾炎气虚血瘀证大鼠模型的药效学研究.广州中医药大学学报,2000；17(4)：332-336.
[15]钟丹,杨霓芝,赵代鑫,等.中药复方通脉口服液配伍前后对肾小球系膜细胞增殖的影响.实用中医内科杂志,2007；21(3)：21-23.
[16]邢海燕,董晓伦.叶任高教授中西医结合治疗慢性肾衰竭的经验.中国中西医结 合肾病杂志,2002；3(9)：502-503.
[17]张勉之.张大宁诊治慢性肾功能衰竭的思路与方法.中医杂志,2007；48(9)：846-848.
[18]沈庆法.慢性肾衰竭的中医药治疗作用.上海中医药杂志,2006；40(9)：37.
[19]王斌.陈以平教授治疗慢性肾功能不全经验探讨.福建中医药,2003；34(5)：17.
[20]朱戎.陈以平治疗慢性肾功能衰竭经验撷菁.辽宁中医杂志,2005；32(7)：648-650.
[21]郭鹏,欧阳静萍,毛先晴,等.黄芪多糖对2型糖尿病KKAy小鼠早期肾脏病理改变的影响.武汉大学学报(医学版),2007；28(1)：74-76.
[22]Zhang JF, Wang GH, Yang XQ. Effects of a stragdus extract on atherosis. Journal of Biomedical Engineering,2005; 22(3):169-170.
[23]张敬芳,吴勇,欧阳静萍.黄芪多糖降糖作用及其对蛋白激酶B和葡萄糖转运蛋白4的影响.中华内分泌代谢杂志,2008；24(5)：1058-1061.
[24]阮雪玲,张秀薇,等.黄芪和丹参注射液联用对早期糖尿病肾病血液流变学和肾功能的影响.中国实用内科学杂志,2005；2：147.
[25]程晖,贾汝汉,刘红燕.黄芪对糖尿病大鼠肾脏的保护作用.中国医师杂志,2006；8(10)：1349—1351.
[26]阮耀,岳兴如,徐持华,等.黄芪对早期糖尿病大鼠心肌非酶糖基化及氧化应激反应的影响.中药药理与临床,2008；24(1)：47—49.
[27]沈健.黄芪注射液对AGKs培养肾小球系膜细胞的影响.中成药,2006；28(8)：1170-1174.
[28]杨霓芝,包昆,王立新,等.通脉口服液对慢性肾炎气虚血瘀证大鼠模型的药效学研究.广州中医药大学学报,2000；17(4)：332-336.
[29]王立新,杨霓芝,包昆,等.通脉口服液对系膜增殖性肾炎大鼠血液流变学的影响.中医药研究,2001；17(1)：42-43.
[30]程甦,屠庆年,陆付耳.三七总苷对糖尿病大鼠早期肾脏高滤过及血管内皮功能的影响.医药导报,2005；24(6)：467-470.
[31]屠庆年,陆付耳.三七总甙对糖尿病肾病大鼠血栓素B2及6-酮-前列腺素F1α的影响.中国中西医结合消化杂志,2005；13(4)：253—255.
[32]程甦,屠庆年,陆付耳.三七总苷对糖尿病大鼠早期肾脏高滤过及血管内皮功能的影响.医药导报,2005；24(6)：467—470.
[33]张征宇,孙澍彬.三七总苷注射液辅助治疗早期糖尿病肾病患者的疗效观察.中国中西医结合肾病杂志,2005；6(7)：407—409.
[34]李忠亮,常冰玲.血塞通治疗糖尿病肾病的疗效观察.中国误诊学杂志,2005； 5(11)：2031—2032.
[35]贾秀琴,李雪梅.中药抗肾纤维化用药规律探析.中国中西医结合肾病杂志,2006；7(12)：739-740.
[36]王峰,张才军,王玲.人工培养冬虫夏草提取物免疫调节试验研究进展.医学综述,2008；14(6)：933—935.
[37]费忠化,唐德燊,刘华锋,等.延缓慢性肾衰竭进展的综合措施及相关新进展.国外医学泌尿系统分册,2005；3(25)：396-400.
[38]李澄湘.丹参酮Ⅱ A磺酸钠在慢性肾功能不全患者中的应用.医学临床研究,2007；24(6)：1041-1042.
[39]孙兴旺,曹灵,于国华,等.丹参酮ⅡA磺酸钠对人肾间质成纤维细胞体外增殖及cyclin E蛋白表达的影响.第三军医大学学报,2007；29(7)：585-587.
[40]蒲超,杨亦彬,孙全林,等.复方丹参片对维持性血液透析患者氧化应激和微炎症状态的干预作用.中国中西医结合杂志,2006；26(9)：793.
[41]季亢挺,张怀勤,唐疾飞,等.丹参对高胆固醇血症患者内皮祖细胞数量及功能的影响.中国中药杂志,2007；32(12)：1214-1217.
[42]蔡光先,赵玉庸.慢性肾衰竭治疗.中西医结合内科学,2005,8：460-465.
[43]宓静英,李洪亮,卑占宇,等.六月雪水提取物耐缺氯作用的研究赣南医学院学报,2006；26(6)：826-827.
[44]朱秋萍,李洪亮,范小娜.六月雪提取物对小鼠免疫作用的影响.赣南医学院学报,2007；27(1)：11-12.
[45]蔡英兰,李相伍,金香子.榛花对糖尿病小鼠血清SOD活性及MDA含量的影响.延边大学医学学报,2005；28(4)：251.
[46]薄守波,鞠建伟,李建远,等.褐藻多糖硫酸酯对人肾小球系膜细胞增殖及纤连蛋白与转化生长因子分泌的影响.中华肾脏病杂志,2006；22(10)：638—639.
[47]廖昌龙,李启运.海藻酸钙对腺嘌呤诱导慢性肾小管—间质病变的保护作用.中国药理学通报,2002；18(4)：480.
[48]刘迟,胡仲仪.莪术对肾间质病变引起的早期慢性肾功能衰竭影响的临床观察.上海中医药杂志,2004；38(11)：15—16.
[49]王立新,杨霓芝,包昆,等.通脉口服液对慢性肾炎气虚血瘀证免疫功能的影响.中医药研究,2000；16(5)：16-18.
[50]钟丹,杨霓芝,赵代鑫,等.中药复方“通脉口服液”治疗慢性肾炎气虚血瘀证的临床研究.井冈山学院学报(自然科学),2007；28(8)：88-91.
[51]钟丹,毛炜,杨霓芝,等.中药复方通脉口服液对IL-1β导肾小球系膜细胞ERK通路活化的影响.辽宁中医杂志,2007；34(8)：1053-1056.
[52]范萍,杨霓芝.通脉口服液对实验性糖尿病肾病模型大鼠肾脏病理及转化生长 因子β1的影响.广州中医药大学学报,2008；25(6)：514-518.
[53]范萍,郝莉,郑发春,等.通脉口服液干预实验性糖尿病肾病模型大鼠的实验研究.中国中医急症,2009；18(1)：93-95.
[54]孙骏,何立群.纤灵冲剂对大鼠体外肾系膜细胞增殖及分泌ECM影响的研究.中华现代临床医学杂志,2005；3(17)：1765-1767.
[55]何立群,王怡,曹和欣,等.抗纤灵冲剂对慢性肾衰模型肾组织NF-mRNA、PDGF-mRNA的影响.中国实验方剂学杂志,2003；9(5)：29-32.
[56]张春艳,王建明,张佩青.参芪地黄冲剂对慢性肾衰血流动力学的影响.现代中西医结台杂志,2001；10(23)：2229-2230.
[57]周爱香,李小芹,吴子伦,等.慢肾康胶囊对大鼠C-BSA肾炎的治疗作用观察.中国实验方剂学杂志,2002；8(2)：34-38.
[58]施志琴,郑平东.肾衰煎剂治疗慢性肾功能衰竭中长期疗效观察.上海中医药大学学报,2002；16(2)：34—35.
[59]常玲玲,郑广程,武文斌,等.肾安丸对慢性肾衰竭患者脂质代谢的影响.中国中西医结合肾病杂志,2001；2(5)：296-297.
[60]卢富华,徐大基,侯海晶.尿毒康对慢肾衰阳虚大鼠肾组织TGFβ1和CTGF表达的影响.辽宁中医杂志,2008；35(3)：462-463.
[61]于敏,韩冰,史耀勋,等.尿毒康灌肠液对慢性肾衰竭治疗作用的机理探析.中国中医急症,2009；18(3)：392-400.
[62]王颖,童延清,于敏,等.尿毒康灌肠液治疗5／6肾切除大鼠慢性肾衰模型实验研究.中华中医药学刊,2007；25(9)：1844-1845.
[63]韩家强,李仁善.温脾汤治疗慢性肾衰脾肾阳虚证对肾血流动力学的影响.黑龙江中医药,2001；(1)：11.
[64]金艳,王济生,赵旭涛.肾康灵对肾大部切除大鼠肾脏的保护作用国.中西医结合肾病杂志,2007；8(6)：332-334.
[65]郑健,吴群励,林青.肾康灵干预阿霉素肾病大鼠NF—kB的实验研究.福建中医学院学报,2005；15(2)：20-23.
[66]刘光珍,肖红霞,刘兆峰,等.肾康灵胶囊对IgA肾病大鼠的实验研究.中国中西医结合肾病杂志,2003；4(2)：110-111.
[67]郑健,吴群励,郑建洵,等.肾康灵对阿霉素肾病大鼠血栓素B2和6-酮-前列腺素Fla的影响中医杂志,2004；45(8)：619-622.
[68]孙文才,云浩,石明军,等.圣达欣抗肾间质纤维化的实验研究.中国中西医结合肾病杂志,2003；4(1)：13.
[69]孙万森,吴喜利,乔成林,等.益肾降脂方对慢性肾功能衰竭大鼠肾小球系膜细胞增殖的影响.中国中医药信息杂志,2006；13(9)：36-37.
[70]刘润侠,吴喜利,刘艳巧,等.益肾降脂胶囊对慢性肾功能衰竭大鼠整体肾功能及血脂的影响.中国中医急症,2003；12(3)：256.
[71]孙万森,吴喜利,刘润侠,等.益肾降脂胶囊对肾病综合征患者血清IL-6和TNF-α含量的影响.西安交通大学学报(医学版),2005；26(2)：189-190.
[72]刘丽,朱晓雷,王钢,等.保肾片对大鼠肾间质成纤维细胞作用的实验研究.中国中医基础医学杂志,2002；8(5)：50-52.
[73]倪斌,仲昱,王钢.保肾片对慢性肾功能衰竭大鼠血浆ET—1,TXB2及6-keto-PGF1α的影响.南京中医药大学学报(自然科学版),2001；17(2)：93-95.
[74]王钢,孔薇,仲昱,等.保肾片对系膜细胞机械性伸展诱导的增殖因子和细胞外基质成分的影响.中国中西医结合肾病杂志,2003；4(1)：6-9.
[75]苏艳阳,刘颖.肾康宁对急性肾炎家兔ICAM-1和IL-6表达的影响.沈阳医学院学报,2009；11(3)：154-155.
[76]谭大琦,李卫星,李秋华,等.肾安颗粒治疗大鼠CRF的实验研究.中国药理通讯,2003；20(1)：59.
[77]王小琴,邵朝弟,谭大琦,等.肾安颗粒治疗慢性肾衰竭的临床研究.中国中西医结合肾病杂志,2003；4(7)：393-395.
[78]汤水福,陈刚毅,洪钦国,等.尿毒清胶囊及其拆方对5／6肾切除大鼠肾组织TGF-β1 mRNA表达的影响.广州中医药大学学报,2008；25(6)：537-539.
[79]钟伟强,刘冠贤,黄仲良,等.尿毒清对慢性肾衰竭脂质代谢紊乱及肾功能的影响.中国中西医结合肾病杂志,2004；5(8)：458-459.
[80]王莉,桂保松,付荣国,等.尿毒清颗粒对慢性肾功能不全患者血脂的影响.现代中西医结合杂,2009；18(14)：1579—1580.
[81]陈姝君,陈海平,刘奇.尿毒清颗粒对糖尿病大鼠足细胞损伤的保护作用研究.中国中西医结合肾病杂志,2008；9(10)：875-878.
[82]丁跃玲,赵玉庸,陈志强,等.肾络通对阿霉素肾病大鼠肾小管间质增殖细胞核抗原表达的影响.中国中医基础医学杂志,2004；10(1)：48—50.
[83]赵宗江,魏晨,杨美娟,等.复方鳖甲软肝片防治大鼠腺嘌呤慢性肾衰竭作用的实验研究.中国中西医结合肾病杂志,2005；6(12)：687—690.
[84]郭丽萍,袁发焕,张耀全.延肾胶囊对部分肾切除大鼠肾脏CB表达的影响.中国中西医结合肾病杂志,2006；7(3)：143—145.
[85]袁发焕,李一标.延肾胶囊延缓残肾损伤的实验研究.西部医学,2004；16(1)：14—19.
[86]王志萍,张煜.隔药灸结合血透治疗慢性肾功能衰竭疗效观察.中国针灸,2000；20(3)’：136-138.
[87]周燕萍,邓丽丽,张洁婷.中药全结肠透析治疗慢性肾衰的疗效及护理要点.中 医药导报,2009；15(5)：74-75.
[88]李慧,柴可夫,楼基伟.益肾活血方治疗慢性肾衰的实验研究.浙江中医学院学报,2000；24(6)：50—51.
[89]刘玉宁,魏小萌,邓伟.肾安胶囊对慢性肾功能衰竭大鼠尿蛋白的影响.国医论坛,2000；15(2)：45—46.
[90]郭立中,毛炜,王红梅,等.肾康注射液对肾小球系膜细胞抑制作用的血清学研究.中国中西医结合杂志,2001；21(7)：531—533.
[91]朱晓玲,王军,周大为,等.复方积雪草防治肾小球硬化的实验研究.：中华肾脏病杂志,2001；17(3)：199—200.
[92]马建伟,刘占民,徐丽梅.滋肾活血解毒方对慢性肾功能衰竭大鼠的疗效观察.成都中医药大学学报,2000；23(1)：52—53.
[93]马建伟,刘占民,徐丽梅,等.滋肾活血解毒方对慢性肾功能衰竭大鼠肾TGF-β1,ET-1mRNA的影响.北京中医,2001；20(3)：45.
[94]徐大基,杨霓芝,李奋.慢性肾功能衰竭.泌尿科专病中医临床诊治[M],北京：人民卫生出版社,2001：422—460.
[95]朱虹,吴强,徐明,等.黄芪总提物体内外抗血栓作用的实验研究.中国临床药理学和治疗学,2005；10(8)：917-920.
[96]龙子江,吕晓英,彭代银,等.虫类药对慢性肾功能不全大鼠的实验研究.中国实验方剂学杂志,2000；6(3)：32—33.
[97]王怡,何立群,郑平东.抗纤灵冲剂改善慢性肾衰实验兔血液动力学及肾小球硬化的研究.上海中医药大学学报,2000；14(2)：47—49.
[98]王小琴,潘向群.肾康冲剂治疗慢性肾衰的实验研究.湖北中医学院学报,2000；2(3)：19—20.
[99]刘玉宁,杜宝荣,刘玉峰,等.肾安胶囊治疗大鼠慢性肾功能衰竭的研究.中国实验方剂学杂志,2000；6(5)：43—44.
[100]张宁,张字忠,齐尔家.补肾活血法改善肾衰大鼠骨代谢异常的实验研究.中国医药学报,2000；15(6)：68—70.
[101]叶任高,阳晓.论慢性肾功能衰竭的进展机制和对策.中国医刊,2002；36(3)：2.
[102]Kuhlmann U, Hoyer J. Can we influence the progression of chronic kidney disease? Urologe A,2009; 48(7):793-803.
[103]Kamper AL, Pedersen EB, Strandgaard S. Hypertension and renal disease. Ugeskr Laeger,2009; 171(25):2109-2113.
[104]Tomlinson LA, Holt SG, Leslie AR,et al. Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4. Nephrol Dial
Transplant,2009; 24(12):3751-3755.
[105]Marin R, Gorostidi M, Alvarez-Navascues R, et al. Treating high blood pressure in kidney patients:evidence and implications. Med Clin(Barc), 2009; 132 Suppl 1:20-26.
[106]Bash LD, Astor BC, Coresh J. Risk of incident ESRD:a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis, 2010; 55(1):31-41.
[107]Schmidt RJ, Latos DL. Chronic kidney disease:the new epidemic and its impact on West Virginia. W V Med J,2009; 105(5):12-16,18.
[108]Glabska D, Narojek L, Wardak J, et al. Analysis of the food rations of predialysis patients with chronic renal failure receiving essential amino acid ketoanalogues.Rocz Panstw Zakl Hig,2009; 60(3):285-288.
[109]Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev,2009; (3):CD001892.
[110]Fouque D, Wang P, Laville M, et al. Low protein diets for chronic renal failure in non diabetic adults. Cochrane Database Syst Rev,2001; (2): CD001892.
[111]Ideura T,Shimazui M, Higuchi K, et al. Effect of nonsupplemented low-protein diet on very late stage CRF. Am J Kidney Dis,2003; 41(3 Suppl 1):s31-34.
[112]Ideura T, Shimazui M, Higuchi K, et al. Effect of nonsupplemented low-protein diet on very late stage CRF. Am J Kidney Dis,2003; 41(3 Suppl 1):s31-34.
[113]Akash, Pande DP, Sharma S, et al. Randomized, doble-blind, placeo-controlled trial to evaluate efficacy of keto diet in predialytic chronic renal failure. DIABETES,2004; 53:820-823.
[114]Nangaku M, Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res,2008; 31(2):175-184.
[115]Erwig LP. Macrophages and hypoxia in human chronic kidney disease. Kidney Int,2008; 74(4):405-406.
[116]Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases:from hypothesis to novel therapeutics. Kidney Int,2008; 74(7):867-872.
[117]Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based
identification of small molecule angiotensinconverting enzyme 2 activators as novel antihypertensive agents. Hypertension,2008; 51(5): 1312-1317.
[118]Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal rotection. Am J Cardiol,2010; 105(1 Suppl):30A-5A.
[119]Tylicki L, Renke M, Rutkowski P, et al. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection:an open, controlled, randomized study. Scand J Urol Nephrol,2008; 42(4):381-388.
[120]Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev,2009; (3):CD007004.
[121]Maione A, Strippoli GF. Risk factors for the development and progression of renal diseases in disadvantaged populations:role of the renin-angiotensin system blockade. Ethn Dis,2009; 19(1 Suppl 1):Sl-86-9.
[122]Monhart V. Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease. Vnitr Lek,2009; 55(7-8):671-678.
[123]Hamoma K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis, 2002; 39(4):695-705.
[124]Brosnahan G, Fraer M. Chronic kidney disease:whom to screen and how to treat, part 1 definition, epidemiology, and laboratory testing. South Med J,2010; 103(2):140-146.
[125]赵文鹏,刘建.慢性肾功能衰竭证治浅谈.河北中医,2003；25(4)：282-283.
[126]远英.大黄素对人肾成纤维细胞增殖的影响.中西医结合杂志,2000；20(2)：105.
[127]叶传蕙.中医药治疗慢性肾功能衰竭思路与方法.中国临床医生,2002；30(1)：51-53.
[128]周同,吴佩.细胞黏附分子与血栓形成.见王鸿利,王学锋主编：血栓病临床新技术[M],第1版,北京：人民军医出版社,2003：67-80.
[129]Mcever RP. Selectin [M]. in:Beckerle MC, Cell adhesion, Oxford:Oxford University Press,2002:30-61.
[130]Au PY, Martin N, Chau H, et al. The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF. Oncogene, 2005; 24
(19)：3196-3205.
[131]万鸿君,彭芳,李艳.慢性肾功能不全患者血清TNF-α水平的变化.临床内科杂志,2005：22(11)：775-776.
[132]孙晓明,罗南萍,杨道理.CD44与CD62P在肾脏疾病中的表达及意义.免疫学杂志,2000；16(1)：52-54.
[133]姚兰兰,陈新焰,许凤,等.高尿酸血症TNF-α启动子区基因多态性与其代谢表型的关系.中国现代医生,2008；46(1)：1-3.
[135]孙晓红.慢性肾衰竭中细胞因子及与左心功能.中国血液净化,2004；3(4)：216-219.
[136]Sebekova K, Podracka L, Heidland A,et al. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related? Clin Nephrol,2001; 56(6):S21-6.
[137]齐法莲,徐军,武翠华,等.慢性肾衰患者血清IL-18、 IL-10、 sIL-2R、 TNF-α水平变化.放射免疫学杂志,2006；19(3)：178-179.
[134]陈香美.细胞外基质降解系统在肾脏疾病中作用的研究.解放军医学杂志,2001；26(12)：861-863.
[138]Buraczynska M, Mierzicki P, Buraczynska K, et al. Tumor necrosis factor-alpha gene polymorphism correlates with cardiovascular disease in patients with end-stage renal disease. Mol Diagn Ther,2007; 11(4):257-263.
[139]程军,张雯,陶筱娟,等.IgA肾病小鼠肾皮质PDGF-β、 PDGFR-βmRNA表达的研究.医学研究杂志,2008；37(5)：53-55.
[140]徐惠,官阳,杨木兰,等.PDGF及P DGFR在大鼠肾间质纤维化过程中的作用.中国现代医学杂志,2007；17(19)：2354-2357.
[141]姜晓宇,袁伟杰.PDGF对大鼠肾小球系膜细胞表达纤维连接蛋白和PAI—1的影响.山东学学报(医学版),2005；43(10)：934-937.
[142]邢燕.肾脏疾病细胞凋亡.国外医学泌尿系统分册,2003；23(2)：222-224.
[143]王琼书.细胞凋亡与肾脏疾病.实用医学杂志,2004；20(10)：1193-1195.
[144]Raj DS, Shah H, Shah VO, et al. Markers of inflammation, proteolysis, and apoptosis in ESRD. Am J Kidney Dis,2003; 42(6):1212-1220.
[145]Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol, 2004; 15(8):1983-1992.
[146]Makulska I, Zwolinska D, Chybicka A, et al. Apoptosis in patients with
chronic renal failure (CRF). Przegl Lek,2006; 63 Suppl 3:180-183.
[147]Wang W,Tzanidis A,Divjak M, et al. Altered signaling and regulatory mechanisms of apoptosis in focal and segmental glomerulosclerosis. J Am Soc Nephrol,2001; 12(7):1422-1423.
[148]杨晓,沈延春,朱忠华,等.大鼠残肾细胞凋亡及凋亡相关基因的动态表达及意义.中国病理生理杂志,2007；23(5)：916—920.
[149]王琛,李忻,李平,等.肾小球系膜细胞凋亡研究进展.中国中西医结合杂志,2006；7(11)：671-672.
[150]Makulska I, Zwolinska D, Chybicka A, et al. Apoptosis in patients with chronic renal failure (CRF).Przegl Lek.2006; 63 Suppl 3:180-183.
[151]Kaliuzhina EV, Geinits OA, Kaliuzhin VV, et al. The condition of immune homeostasis in patients with chronic renal failure. Klin Med (Mosk).2006; 84(11):60-63.
[152]Meier P, Golshayan D, Blanc E, et al.Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol,2009; 20(6):1368-1384.
[153]Hendrikx TK, van Gurp EA, Mol WM, et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant,2009; 24(6):1969-1978.
[154]Meier P, Meier R, Blanc E. Influence of CD4+/CD25+regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther,2008; 6(7):987-997.
[155]Hendrikx TK, van Gurp EA, Mol WM, et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+T-cells. Nephrol Dial Transplant,2009; 24(6):1969-1978.
[156]Betjes MG, Huisman M, Weimar W, et al. Expansion of cytolytic CD4+CD28-Tcells in end-stage renal disease. Kidney Int,2008; 74(6):760-767.
[157]Meier P, Dayer E, Ronco P,et al. Dysregulation of IL-2/IL-2R system alters proliferation of early activated CD4+ T cell subset in patients with end-stage renal failure. Clin Nephrol,2005; 63(1):8-21.
[158]贺发贵,徐应军,周柱亮.肾综合征出血热患者肾组织中CD4和CD8细胞浸润的临床意义.中国医师杂志,2006；8(8)：1113-1114.
[159]戴璐,刘学光,张秀荣,等.狼疮性肾炎病变肾组织中BFGF、 CD68和PCNA表达的研究.中国组织化学与细胞化学杂志,2003；12(4)：356-359.
[160]胡旭光,臧建伟,唐春萍,等.六味地黄汤生物制剂对肾阴虚小鼠脾T淋巴细 胞亚群的影响.时珍国医国药,2008；19(5)：1033-1034.
[161]蒋伟芳.金水宝胶囊对PNs患者CD4+、 CD4+/CD8+的影响研究.临床药学,2009；10：38.
[162]迟继铭,徐丹,王晶,等.补脾益气升阳方对糖尿病大鼠肾组织CD68标记巨噬细胞表达的影响.中国中西医结合肾病杂志,2009；10(8)：720-722.
[163]王海燕,郑法雷,刘玉春,等.原发性肾小球疾病分型与治疗及诊断标准专题座谈会纪要.中华内科杂志,1993：32(2)：131-134.
[164]中华中医药学会肾病分会.慢性肾衰竭的诊断、辨证分型及疗效评定.上海中医药杂志,2006,40(8)：8—9.
[165]艾永顺,刘丽君,费瑜,等.不稳定性心绞痛患者血清P选择素、可溶性细胞间黏附因子-1的变化及奥扎格雷对其影响.中国实验诊断学,2005；(4)：79—805.
[166]Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertensionwere improved by continuous pmstacyclin therapy. Circulation,2000; 102: 2720-2725.
[167]王峰,范存亮,蔡尚郎.血浆可溶性选择素在急性冠脉综合征诊疗中的应用.人民军医,2005；(4)：43-46.
[168]Andre P. Hartwell D. Hrachovinova I, et al. Pro-coagulant state resulting from high levels of soluble P selectin in blood. Proc NadAcad Sci USA,2000：97：13835—13840.
[169]Conway DSG, Pearce LA, Chin BSP, et al. Plasma VOII Willebrandfactor and soluble P-selectin a8 indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillHtion. Cimulation,2002; 106:1962-1967.
[170]孙小梅,姚琰,纪三姣,等.三七总皂甙对冠心病病人血浆内颗粒膜蛋白和血小板聚集的影响.数理医药学杂志,2001；14(1)：26-27.
[171]陈运,袁灿兴,顾明昌.血塞通注射液治疗急性脑梗死临床观察.中医临床医学,2004；11(5)：873—875.
[172]余静,郭雪娅,赵锋,等.黄芪注射液对高血压病患者血浆P选择素、血栓素及6-酮-前列腺素F1的影响.临床荟萃,2005；20(13)：721—723.
[173]何立群,邵命海,侯卫国,等.活血化瘀法对血瘀型早、中期慢性肾衰竭疗效评价及作用途径.医学研究,2007；36(7)：70.
[174]王阶,许军,衷敬柏,等.三七总苷对高黏血症患者血小板活化分子表达和血小板聚集的影响.中国中西医结合杂志,2004；24(4)：312—316.
[175]施新猷.医用实验动物学,第2版[M].北京：人民卫生出版社,2000：400-401.
[176]叶任高,沈清瑞.肾脏病诊断与治疗学[M].北京：人民卫生出版社,1996：206—207.
[177]陈世件,胡碧容.慢性肾衰竭患者CD62P和CD63水平及灯盏花对其影响的研究.中国中西医结合肾病杂志,2002；3(11)：661-662.
[178]韦芳宁,杨霓芝.血小板膜糖蛋白与慢性肾功能衰竭.实用医学杂志,2009；25(2)：316-317.
[179]热娜古丽·艾则孜,哈木拉提·吾甫尔,金伟.血栓前状态分子标志物的研究进展.新疆医学,2007；37：111-113.
[180]余国忠.P选择素与血小板活化.中国医药导刊,2006；8(2)：108-109.
[181]朱月文.慢性肾功能衰竭患者CD62P表达与肾功能的关系.浙江临床医学,2006；8(6)：597-598.
[182]戴勇,李富荣,贺晓蕾,等.慢性肾功能不全患者外周血血小板P—选择素、L-选择素和细胞间粘附分子-1表达的研究.中国现代医学杂志,2003；13(8)：31-33.
[183]蒋亚平.血小板粘附分子在慢性肾功能衰竭中的变化及意义.河北医学,2005；11(6)：575-577.
[184]韦芳宁,杨霓芝,黄宪章,等.益气活血中药血液透析液对慢性肾功能衰竭患者血小板膜糖蛋白CD62P表达的影响.中国中西医结合杂志,2007；2(2)：106-109.
[185]宋锦叶,李深,孟力强,等.黄芪当归合剂对5／6肾切除大鼠肾组织损伤的治疗作用.北京大学学报：医学版,2009；41(2)：196-202.
[186]万鸿君,彭芳,李艳.慢性肾功能不全患者血清TNF-α水平的变化.临床内科杂志,2005；22(11)：775-776.
[187]唐学飞.肾功能衰竭出血病人血液透析体外循环抗凝新研讨.中医药导报,2006；3(14)：36.
[188]甘晓斌,慢性肾功能衰竭患者TNF-α和CD62P的表达及意义.中外医疗,2008；10：5-6.
[189]FedulovAV, SesTP, Gavrisheva NA, et al. Serum TGF-beta 1 and TNF-alpha levels and cardiac fibrosis in experimental chronic renal failure. Immunol Invest,2005; 34(2):143-52.
[190]杨朝晖,甘华.细胞因子对肾间质纤维化形成的影响.中国现代医学杂志,2004；14(5)：50—53.
[191]周剑锋.BMP7／BMP7R／Smads、TGFβ1与肾纤维化.重庆医学,2006；3(18)：1709-1711.
[192]Zeisberg M,Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverseschronic renal injury. Nat Med,2003； 9:964-968.
[193]马云波.TGF-β与肾小管间质肾炎关系的研究进展.国际泌尿系统杂志,2007；27(4)：537-541.
[2]陈孝文,梁东,刘华锋,主编.慢性肾衰竭[M].北京：中国医药科技出版社,2006：25,148.
[3]Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population:Third National Health and Nutrition Examination Survey. Am J Kidney Dis,2003; 41(1): 1-12.
[4]张路霞,左力,徐国宾,等.北京市石景山地区中老年人群中慢性肾脏病的流行病学研究.中华肾脏病杂志,2006；22(2)：67-71.
[5]Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcomes. Kidney Int,2004; 66(4):1310-1314.
[6]Lysaght MJ. Maintenance dialysis population dynamics:current trends and long-term implications.J Am Soc Nephrol,2002; 13 Suppl 1:S37-40.
[7]Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection:frustration and promises. Kidney Int,2003; 64(6):1947-1955.
[8]Hamoma K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis,2002; 39(4):695-705.
[9]杨霓芝,王立新,林启展,等.通脉口服液治疗慢性肾炎气虚血瘀证32例疗效观察.新中医,2003；35(1)：19-21.
[10]王立新,杨霓芝,包昆,等.通脉口服液对系膜增殖性肾炎大鼠血液流变学的影响.中医药研究,2001；17(1)：42-43.
[11]杨霓芝,包昆,王立新,等通脉口服液对大鼠慢性肾炎“气虚血瘀证”模型的组织形态学影响.中国中医药信息杂志,2001；8(3)：31-33.
[12],杨霓芝,钟丹,赵代鑫,等.通脉口服液对肾小球系膜细胞增殖及白细胞介素β1、白细胞介素10表达的影响.中国西医结合肾病杂志,2007；8(8)：444-447.
[13]钟丹,杨霓芝,赵代鑫,等.中药复方“通脉口服液”对肾小球系膜细胞增殖及分泌IL-1β的影响.时珍国医国药,2008；19(1)：4-6.
[14]杨霓芝,包昆,王立新,等.通脉口服液对慢性肾炎气虚血瘀证大鼠模型的药效学研究.广州中医药大学学报,2000；17(4)：332-336.
[15]钟丹,杨霓芝,赵代鑫,等.中药复方通脉口服液配伍前后对肾小球系膜细胞增殖的影响.实用中医内科杂志,2007；21(3)：21-23.
[16]邢海燕,董晓伦.叶任高教授中西医结合治疗慢性肾衰竭的经验.中国中西医结 合肾病杂志,2002；3(9)：502-503.
[17]张勉之.张大宁诊治慢性肾功能衰竭的思路与方法.中医杂志,2007；48(9)：846-848.
[18]沈庆法.慢性肾衰竭的中医药治疗作用.上海中医药杂志,2006；40(9)：37.
[19]王斌.陈以平教授治疗慢性肾功能不全经验探讨.福建中医药,2003；34(5)：17.
[20]朱戎.陈以平治疗慢性肾功能衰竭经验撷菁.辽宁中医杂志,2005；32(7)：648-650.
[21]郭鹏,欧阳静萍,毛先晴,等.黄芪多糖对2型糖尿病KKAy小鼠早期肾脏病理改变的影响.武汉大学学报(医学版),2007；28(1)：74-76.
[22]Zhang JF, Wang GH, Yang XQ. Effects of a stragdus extract on atherosis. Journal of Biomedical Engineering,2005; 22(3):169-170.
[23]张敬芳,吴勇,欧阳静萍.黄芪多糖降糖作用及其对蛋白激酶B和葡萄糖转运蛋白4的影响.中华内分泌代谢杂志,2008；24(5)：1058-1061.
[24]阮雪玲,张秀薇,等.黄芪和丹参注射液联用对早期糖尿病肾病血液流变学和肾功能的影响.中国实用内科学杂志,2005；2：147.
[25]程晖,贾汝汉,刘红燕.黄芪对糖尿病大鼠肾脏的保护作用.中国医师杂志,2006；8(10)：1349—1351.
[26]阮耀,岳兴如,徐持华,等.黄芪对早期糖尿病大鼠心肌非酶糖基化及氧化应激反应的影响.中药药理与临床,2008；24(1)：47—49.
[27]沈健.黄芪注射液对AGKs培养肾小球系膜细胞的影响.中成药,2006；28(8)：1170-1174.
[28]杨霓芝,包昆,王立新,等.通脉口服液对慢性肾炎气虚血瘀证大鼠模型的药效学研究.广州中医药大学学报,2000；17(4)：332-336.
[29]王立新,杨霓芝,包昆,等.通脉口服液对系膜增殖性肾炎大鼠血液流变学的影响.中医药研究,2001；17(1)：42-43.
[30]程甦,屠庆年,陆付耳.三七总苷对糖尿病大鼠早期肾脏高滤过及血管内皮功能的影响.医药导报,2005；24(6)：467-470.
[31]屠庆年,陆付耳.三七总甙对糖尿病肾病大鼠血栓素B2及6-酮-前列腺素F1α的影响.中国中西医结合消化杂志,2005；13(4)：253—255.
[32]程甦,屠庆年,陆付耳.三七总苷对糖尿病大鼠早期肾脏高滤过及血管内皮功能的影响.医药导报,2005；24(6)：467—470.
[33]张征宇,孙澍彬.三七总苷注射液辅助治疗早期糖尿病肾病患者的疗效观察.中国中西医结合肾病杂志,2005；6(7)：407—409.
[34]李忠亮,常冰玲.血塞通治疗糖尿病肾病的疗效观察.中国误诊学杂志,2005； 5(11)：2031—2032.
[35]贾秀琴,李雪梅.中药抗肾纤维化用药规律探析.中国中西医结合肾病杂志,2006；7(12)：739-740.
[36]王峰,张才军,王玲.人工培养冬虫夏草提取物免疫调节试验研究进展.医学综述,2008；14(6)：933—935.
[37]费忠化,唐德燊,刘华锋,等.延缓慢性肾衰竭进展的综合措施及相关新进展.国外医学泌尿系统分册,2005；3(25)：396-400.
[38]李澄湘.丹参酮Ⅱ A磺酸钠在慢性肾功能不全患者中的应用.医学临床研究,2007；24(6)：1041-1042.
[39]孙兴旺,曹灵,于国华,等.丹参酮ⅡA磺酸钠对人肾间质成纤维细胞体外增殖及cyclin E蛋白表达的影响.第三军医大学学报,2007；29(7)：585-587.
[40]蒲超,杨亦彬,孙全林,等.复方丹参片对维持性血液透析患者氧化应激和微炎症状态的干预作用.中国中西医结合杂志,2006；26(9)：793.
[41]季亢挺,张怀勤,唐疾飞,等.丹参对高胆固醇血症患者内皮祖细胞数量及功能的影响.中国中药杂志,2007；32(12)：1214-1217.
[42]蔡光先,赵玉庸.慢性肾衰竭治疗.中西医结合内科学,2005,8：460-465.
[43]宓静英,李洪亮,卑占宇,等.六月雪水提取物耐缺氯作用的研究赣南医学院学报,2006；26(6)：826-827.
[44]朱秋萍,李洪亮,范小娜.六月雪提取物对小鼠免疫作用的影响.赣南医学院学报,2007；27(1)：11-12.
[45]蔡英兰,李相伍,金香子.榛花对糖尿病小鼠血清SOD活性及MDA含量的影响.延边大学医学学报,2005；28(4)：251.
[46]薄守波,鞠建伟,李建远,等.褐藻多糖硫酸酯对人肾小球系膜细胞增殖及纤连蛋白与转化生长因子分泌的影响.中华肾脏病杂志,2006；22(10)：638—639.
[47]廖昌龙,李启运.海藻酸钙对腺嘌呤诱导慢性肾小管—间质病变的保护作用.中国药理学通报,2002；18(4)：480.
[48]刘迟,胡仲仪.莪术对肾间质病变引起的早期慢性肾功能衰竭影响的临床观察.上海中医药杂志,2004；38(11)：15—16.
[49]王立新,杨霓芝,包昆,等.通脉口服液对慢性肾炎气虚血瘀证免疫功能的影响.中医药研究,2000；16(5)：16-18.
[50]钟丹,杨霓芝,赵代鑫,等.中药复方“通脉口服液”治疗慢性肾炎气虚血瘀证的临床研究.井冈山学院学报(自然科学),2007；28(8)：88-91.
[51]钟丹,毛炜,杨霓芝,等.中药复方通脉口服液对IL-1β导肾小球系膜细胞ERK通路活化的影响.辽宁中医杂志,2007；34(8)：1053-1056.
[52]范萍,杨霓芝.通脉口服液对实验性糖尿病肾病模型大鼠肾脏病理及转化生长 因子β1的影响.广州中医药大学学报,2008；25(6)：514-518.
[53]范萍,郝莉,郑发春,等.通脉口服液干预实验性糖尿病肾病模型大鼠的实验研究.中国中医急症,2009；18(1)：93-95.
[54]孙骏,何立群.纤灵冲剂对大鼠体外肾系膜细胞增殖及分泌ECM影响的研究.中华现代临床医学杂志,2005；3(17)：1765-1767.
[55]何立群,王怡,曹和欣,等.抗纤灵冲剂对慢性肾衰模型肾组织NF-mRNA、PDGF-mRNA的影响.中国实验方剂学杂志,2003；9(5)：29-32.
[56]张春艳,王建明,张佩青.参芪地黄冲剂对慢性肾衰血流动力学的影响.现代中西医结台杂志,2001；10(23)：2229-2230.
[57]周爱香,李小芹,吴子伦,等.慢肾康胶囊对大鼠C-BSA肾炎的治疗作用观察.中国实验方剂学杂志,2002；8(2)：34-38.
[58]施志琴,郑平东.肾衰煎剂治疗慢性肾功能衰竭中长期疗效观察.上海中医药大学学报,2002；16(2)：34—35.
[59]常玲玲,郑广程,武文斌,等.肾安丸对慢性肾衰竭患者脂质代谢的影响.中国中西医结合肾病杂志,2001；2(5)：296-297.
[60]卢富华,徐大基,侯海晶.尿毒康对慢肾衰阳虚大鼠肾组织TGFβ1和CTGF表达的影响.辽宁中医杂志,2008；35(3)：462-463.
[61]于敏,韩冰,史耀勋,等.尿毒康灌肠液对慢性肾衰竭治疗作用的机理探析.中国中医急症,2009；18(3)：392-400.
[62]王颖,童延清,于敏,等.尿毒康灌肠液治疗5／6肾切除大鼠慢性肾衰模型实验研究.中华中医药学刊,2007；25(9)：1844-1845.
[63]韩家强,李仁善.温脾汤治疗慢性肾衰脾肾阳虚证对肾血流动力学的影响.黑龙江中医药,2001；(1)：11.
[64]金艳,王济生,赵旭涛.肾康灵对肾大部切除大鼠肾脏的保护作用国.中西医结合肾病杂志,2007；8(6)：332-334.
[65]郑健,吴群励,林青.肾康灵干预阿霉素肾病大鼠NF—kB的实验研究.福建中医学院学报,2005；15(2)：20-23.
[66]刘光珍,肖红霞,刘兆峰,等.肾康灵胶囊对IgA肾病大鼠的实验研究.中国中西医结合肾病杂志,2003；4(2)：110-111.
[67]郑健,吴群励,郑建洵,等.肾康灵对阿霉素肾病大鼠血栓素B2和6-酮-前列腺素Fla的影响中医杂志,2004；45(8)：619-622.
[68]孙文才,云浩,石明军,等.圣达欣抗肾间质纤维化的实验研究.中国中西医结合肾病杂志,2003；4(1)：13.
[69]孙万森,吴喜利,乔成林,等.益肾降脂方对慢性肾功能衰竭大鼠肾小球系膜细胞增殖的影响.中国中医药信息杂志,2006；13(9)：36-37.
[70]刘润侠,吴喜利,刘艳巧,等.益肾降脂胶囊对慢性肾功能衰竭大鼠整体肾功能及血脂的影响.中国中医急症,2003；12(3)：256.
[71]孙万森,吴喜利,刘润侠,等.益肾降脂胶囊对肾病综合征患者血清IL-6和TNF-α含量的影响.西安交通大学学报(医学版),2005；26(2)：189-190.
[72]刘丽,朱晓雷,王钢,等.保肾片对大鼠肾间质成纤维细胞作用的实验研究.中国中医基础医学杂志,2002；8(5)：50-52.
[73]倪斌,仲昱,王钢.保肾片对慢性肾功能衰竭大鼠血浆ET—1,TXB2及6-keto-PGF1α的影响.南京中医药大学学报(自然科学版),2001；17(2)：93-95.
[74]王钢,孔薇,仲昱,等.保肾片对系膜细胞机械性伸展诱导的增殖因子和细胞外基质成分的影响.中国中西医结合肾病杂志,2003；4(1)：6-9.
[75]苏艳阳,刘颖.肾康宁对急性肾炎家兔ICAM-1和IL-6表达的影响.沈阳医学院学报,2009；11(3)：154-155.
[76]谭大琦,李卫星,李秋华,等.肾安颗粒治疗大鼠CRF的实验研究.中国药理通讯,2003；20(1)：59.
[77]王小琴,邵朝弟,谭大琦,等.肾安颗粒治疗慢性肾衰竭的临床研究.中国中西医结合肾病杂志,2003；4(7)：393-395.
[78]汤水福,陈刚毅,洪钦国,等.尿毒清胶囊及其拆方对5／6肾切除大鼠肾组织TGF-β1 mRNA表达的影响.广州中医药大学学报,2008；25(6)：537-539.
[79]钟伟强,刘冠贤,黄仲良,等.尿毒清对慢性肾衰竭脂质代谢紊乱及肾功能的影响.中国中西医结合肾病杂志,2004；5(8)：458-459.
[80]王莉,桂保松,付荣国,等.尿毒清颗粒对慢性肾功能不全患者血脂的影响.现代中西医结合杂,2009；18(14)：1579—1580.
[81]陈姝君,陈海平,刘奇.尿毒清颗粒对糖尿病大鼠足细胞损伤的保护作用研究.中国中西医结合肾病杂志,2008；9(10)：875-878.
[82]丁跃玲,赵玉庸,陈志强,等.肾络通对阿霉素肾病大鼠肾小管间质增殖细胞核抗原表达的影响.中国中医基础医学杂志,2004；10(1)：48—50.
[83]赵宗江,魏晨,杨美娟,等.复方鳖甲软肝片防治大鼠腺嘌呤慢性肾衰竭作用的实验研究.中国中西医结合肾病杂志,2005；6(12)：687—690.
[84]郭丽萍,袁发焕,张耀全.延肾胶囊对部分肾切除大鼠肾脏CB表达的影响.中国中西医结合肾病杂志,2006；7(3)：143—145.
[85]袁发焕,李一标.延肾胶囊延缓残肾损伤的实验研究.西部医学,2004；16(1)：14—19.
[86]王志萍,张煜.隔药灸结合血透治疗慢性肾功能衰竭疗效观察.中国针灸,2000；20(3)’：136-138.
[87]周燕萍,邓丽丽,张洁婷.中药全结肠透析治疗慢性肾衰的疗效及护理要点.中 医药导报,2009；15(5)：74-75.
[88]李慧,柴可夫,楼基伟.益肾活血方治疗慢性肾衰的实验研究.浙江中医学院学报,2000；24(6)：50—51.
[89]刘玉宁,魏小萌,邓伟.肾安胶囊对慢性肾功能衰竭大鼠尿蛋白的影响.国医论坛,2000；15(2)：45—46.
[90]郭立中,毛炜,王红梅,等.肾康注射液对肾小球系膜细胞抑制作用的血清学研究.中国中西医结合杂志,2001；21(7)：531—533.
[91]朱晓玲,王军,周大为,等.复方积雪草防治肾小球硬化的实验研究.：中华肾脏病杂志,2001；17(3)：199—200.
[92]马建伟,刘占民,徐丽梅.滋肾活血解毒方对慢性肾功能衰竭大鼠的疗效观察.成都中医药大学学报,2000；23(1)：52—53.
[93]马建伟,刘占民,徐丽梅,等.滋肾活血解毒方对慢性肾功能衰竭大鼠肾TGF-β1,ET-1mRNA的影响.北京中医,2001；20(3)：45.
[94]徐大基,杨霓芝,李奋.慢性肾功能衰竭.泌尿科专病中医临床诊治[M],北京：人民卫生出版社,2001：422—460.
[95]朱虹,吴强,徐明,等.黄芪总提物体内外抗血栓作用的实验研究.中国临床药理学和治疗学,2005；10(8)：917-920.
[96]龙子江,吕晓英,彭代银,等.虫类药对慢性肾功能不全大鼠的实验研究.中国实验方剂学杂志,2000；6(3)：32—33.
[97]王怡,何立群,郑平东.抗纤灵冲剂改善慢性肾衰实验兔血液动力学及肾小球硬化的研究.上海中医药大学学报,2000；14(2)：47—49.
[98]王小琴,潘向群.肾康冲剂治疗慢性肾衰的实验研究.湖北中医学院学报,2000；2(3)：19—20.
[99]刘玉宁,杜宝荣,刘玉峰,等.肾安胶囊治疗大鼠慢性肾功能衰竭的研究.中国实验方剂学杂志,2000；6(5)：43—44.
[100]张宁,张字忠,齐尔家.补肾活血法改善肾衰大鼠骨代谢异常的实验研究.中国医药学报,2000；15(6)：68—70.
[101]叶任高,阳晓.论慢性肾功能衰竭的进展机制和对策.中国医刊,2002；36(3)：2.
[102]Kuhlmann U, Hoyer J. Can we influence the progression of chronic kidney disease? Urologe A,2009; 48(7):793-803.
[103]Kamper AL, Pedersen EB, Strandgaard S. Hypertension and renal disease. Ugeskr Laeger,2009; 171(25):2109-2113.
[104]Tomlinson LA, Holt SG, Leslie AR,et al. Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4. Nephrol Dial
Transplant,2009; 24(12):3751-3755.
[105]Marin R, Gorostidi M, Alvarez-Navascues R, et al. Treating high blood pressure in kidney patients:evidence and implications. Med Clin(Barc), 2009; 132 Suppl 1:20-26.
[106]Bash LD, Astor BC, Coresh J. Risk of incident ESRD:a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis, 2010; 55(1):31-41.
[107]Schmidt RJ, Latos DL. Chronic kidney disease:the new epidemic and its impact on West Virginia. W V Med J,2009; 105(5):12-16,18.
[108]Glabska D, Narojek L, Wardak J, et al. Analysis of the food rations of predialysis patients with chronic renal failure receiving essential amino acid ketoanalogues.Rocz Panstw Zakl Hig,2009; 60(3):285-288.
[109]Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev,2009; (3):CD001892.
[110]Fouque D, Wang P, Laville M, et al. Low protein diets for chronic renal failure in non diabetic adults. Cochrane Database Syst Rev,2001; (2): CD001892.
[111]Ideura T,Shimazui M, Higuchi K, et al. Effect of nonsupplemented low-protein diet on very late stage CRF. Am J Kidney Dis,2003; 41(3 Suppl 1):s31-34.
[112]Ideura T, Shimazui M, Higuchi K, et al. Effect of nonsupplemented low-protein diet on very late stage CRF. Am J Kidney Dis,2003; 41(3 Suppl 1):s31-34.
[113]Akash, Pande DP, Sharma S, et al. Randomized, doble-blind, placeo-controlled trial to evaluate efficacy of keto diet in predialytic chronic renal failure. DIABETES,2004; 53:820-823.
[114]Nangaku M, Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res,2008; 31(2):175-184.
[115]Erwig LP. Macrophages and hypoxia in human chronic kidney disease. Kidney Int,2008; 74(4):405-406.
[116]Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases:from hypothesis to novel therapeutics. Kidney Int,2008; 74(7):867-872.
[117]Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based
identification of small molecule angiotensinconverting enzyme 2 activators as novel antihypertensive agents. Hypertension,2008; 51(5): 1312-1317.
[118]Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal rotection. Am J Cardiol,2010; 105(1 Suppl):30A-5A.
[119]Tylicki L, Renke M, Rutkowski P, et al. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection:an open, controlled, randomized study. Scand J Urol Nephrol,2008; 42(4):381-388.
[120]Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev,2009; (3):CD007004.
[121]Maione A, Strippoli GF. Risk factors for the development and progression of renal diseases in disadvantaged populations:role of the renin-angiotensin system blockade. Ethn Dis,2009; 19(1 Suppl 1):Sl-86-9.
[122]Monhart V. Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease. Vnitr Lek,2009; 55(7-8):671-678.
[123]Hamoma K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis, 2002; 39(4):695-705.
[124]Brosnahan G, Fraer M. Chronic kidney disease:whom to screen and how to treat, part 1 definition, epidemiology, and laboratory testing. South Med J,2010; 103(2):140-146.
[125]赵文鹏,刘建.慢性肾功能衰竭证治浅谈.河北中医,2003；25(4)：282-283.
[126]远英.大黄素对人肾成纤维细胞增殖的影响.中西医结合杂志,2000；20(2)：105.
[127]叶传蕙.中医药治疗慢性肾功能衰竭思路与方法.中国临床医生,2002；30(1)：51-53.
[128]周同,吴佩.细胞黏附分子与血栓形成.见王鸿利,王学锋主编：血栓病临床新技术[M],第1版,北京：人民军医出版社,2003：67-80.
[129]Mcever RP. Selectin [M]. in:Beckerle MC, Cell adhesion, Oxford:Oxford University Press,2002:30-61.
[130]Au PY, Martin N, Chau H, et al. The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF. Oncogene, 2005; 24
(19)：3196-3205.
[131]万鸿君,彭芳,李艳.慢性肾功能不全患者血清TNF-α水平的变化.临床内科杂志,2005：22(11)：775-776.
[132]孙晓明,罗南萍,杨道理.CD44与CD62P在肾脏疾病中的表达及意义.免疫学杂志,2000；16(1)：52-54.
[133]姚兰兰,陈新焰,许凤,等.高尿酸血症TNF-α启动子区基因多态性与其代谢表型的关系.中国现代医生,2008；46(1)：1-3.
[135]孙晓红.慢性肾衰竭中细胞因子及与左心功能.中国血液净化,2004；3(4)：216-219.
[136]Sebekova K, Podracka L, Heidland A,et al. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related? Clin Nephrol,2001; 56(6):S21-6.
[137]齐法莲,徐军,武翠华,等.慢性肾衰患者血清IL-18、 IL-10、 sIL-2R、 TNF-α水平变化.放射免疫学杂志,2006；19(3)：178-179.
[134]陈香美.细胞外基质降解系统在肾脏疾病中作用的研究.解放军医学杂志,2001；26(12)：861-863.
[138]Buraczynska M, Mierzicki P, Buraczynska K, et al. Tumor necrosis factor-alpha gene polymorphism correlates with cardiovascular disease in patients with end-stage renal disease. Mol Diagn Ther,2007; 11(4):257-263.
[139]程军,张雯,陶筱娟,等.IgA肾病小鼠肾皮质PDGF-β、 PDGFR-βmRNA表达的研究.医学研究杂志,2008；37(5)：53-55.
[140]徐惠,官阳,杨木兰,等.PDGF及P DGFR在大鼠肾间质纤维化过程中的作用.中国现代医学杂志,2007；17(19)：2354-2357.
[141]姜晓宇,袁伟杰.PDGF对大鼠肾小球系膜细胞表达纤维连接蛋白和PAI—1的影响.山东学学报(医学版),2005；43(10)：934-937.
[142]邢燕.肾脏疾病细胞凋亡.国外医学泌尿系统分册,2003；23(2)：222-224.
[143]王琼书.细胞凋亡与肾脏疾病.实用医学杂志,2004；20(10)：1193-1195.
[144]Raj DS, Shah H, Shah VO, et al. Markers of inflammation, proteolysis, and apoptosis in ESRD. Am J Kidney Dis,2003; 42(6):1212-1220.
[145]Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol, 2004; 15(8):1983-1992.
[146]Makulska I, Zwolinska D, Chybicka A, et al. Apoptosis in patients with
chronic renal failure (CRF). Przegl Lek,2006; 63 Suppl 3:180-183.
[147]Wang W,Tzanidis A,Divjak M, et al. Altered signaling and regulatory mechanisms of apoptosis in focal and segmental glomerulosclerosis. J Am Soc Nephrol,2001; 12(7):1422-1423.
[148]杨晓,沈延春,朱忠华,等.大鼠残肾细胞凋亡及凋亡相关基因的动态表达及意义.中国病理生理杂志,2007；23(5)：916—920.
[149]王琛,李忻,李平,等.肾小球系膜细胞凋亡研究进展.中国中西医结合杂志,2006；7(11)：671-672.
[150]Makulska I, Zwolinska D, Chybicka A, et al. Apoptosis in patients with chronic renal failure (CRF).Przegl Lek.2006; 63 Suppl 3:180-183.
[151]Kaliuzhina EV, Geinits OA, Kaliuzhin VV, et al. The condition of immune homeostasis in patients with chronic renal failure. Klin Med (Mosk).2006; 84(11):60-63.
[152]Meier P, Golshayan D, Blanc E, et al.Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol,2009; 20(6):1368-1384.
[153]Hendrikx TK, van Gurp EA, Mol WM, et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant,2009; 24(6):1969-1978.
[154]Meier P, Meier R, Blanc E. Influence of CD4+/CD25+regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther,2008; 6(7):987-997.
[155]Hendrikx TK, van Gurp EA, Mol WM, et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+T-cells. Nephrol Dial Transplant,2009; 24(6):1969-1978.
[156]Betjes MG, Huisman M, Weimar W, et al. Expansion of cytolytic CD4+CD28-Tcells in end-stage renal disease. Kidney Int,2008; 74(6):760-767.
[157]Meier P, Dayer E, Ronco P,et al. Dysregulation of IL-2/IL-2R system alters proliferation of early activated CD4+ T cell subset in patients with end-stage renal failure. Clin Nephrol,2005; 63(1):8-21.
[158]贺发贵,徐应军,周柱亮.肾综合征出血热患者肾组织中CD4和CD8细胞浸润的临床意义.中国医师杂志,2006；8(8)：1113-1114.
[159]戴璐,刘学光,张秀荣,等.狼疮性肾炎病变肾组织中BFGF、 CD68和PCNA表达的研究.中国组织化学与细胞化学杂志,2003；12(4)：356-359.
[160]胡旭光,臧建伟,唐春萍,等.六味地黄汤生物制剂对肾阴虚小鼠脾T淋巴细 胞亚群的影响.时珍国医国药,2008；19(5)：1033-1034.
[161]蒋伟芳.金水宝胶囊对PNs患者CD4+、 CD4+/CD8+的影响研究.临床药学,2009；10：38.
[162]迟继铭,徐丹,王晶,等.补脾益气升阳方对糖尿病大鼠肾组织CD68标记巨噬细胞表达的影响.中国中西医结合肾病杂志,2009；10(8)：720-722.
[163]王海燕,郑法雷,刘玉春,等.原发性肾小球疾病分型与治疗及诊断标准专题座谈会纪要.中华内科杂志,1993：32(2)：131-134.
[164]中华中医药学会肾病分会.慢性肾衰竭的诊断、辨证分型及疗效评定.上海中医药杂志,2006,40(8)：8—9.
[165]艾永顺,刘丽君,费瑜,等.不稳定性心绞痛患者血清P选择素、可溶性细胞间黏附因子-1的变化及奥扎格雷对其影响.中国实验诊断学,2005；(4)：79—805.
[166]Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertensionwere improved by continuous pmstacyclin therapy. Circulation,2000; 102: 2720-2725.
[167]王峰,范存亮,蔡尚郎.血浆可溶性选择素在急性冠脉综合征诊疗中的应用.人民军医,2005；(4)：43-46.
[168]Andre P. Hartwell D. Hrachovinova I, et al. Pro-coagulant state resulting from high levels of soluble P selectin in blood. Proc NadAcad Sci USA,2000：97：13835—13840.
[169]Conway DSG, Pearce LA, Chin BSP, et al. Plasma VOII Willebrandfactor and soluble P-selectin a8 indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillHtion. Cimulation,2002; 106:1962-1967.
[170]孙小梅,姚琰,纪三姣,等.三七总皂甙对冠心病病人血浆内颗粒膜蛋白和血小板聚集的影响.数理医药学杂志,2001；14(1)：26-27.
[171]陈运,袁灿兴,顾明昌.血塞通注射液治疗急性脑梗死临床观察.中医临床医学,2004；11(5)：873—875.
[172]余静,郭雪娅,赵锋,等.黄芪注射液对高血压病患者血浆P选择素、血栓素及6-酮-前列腺素F1的影响.临床荟萃,2005；20(13)：721—723.
[173]何立群,邵命海,侯卫国,等.活血化瘀法对血瘀型早、中期慢性肾衰竭疗效评价及作用途径.医学研究,2007；36(7)：70.
[174]王阶,许军,衷敬柏,等.三七总苷对高黏血症患者血小板活化分子表达和血小板聚集的影响.中国中西医结合杂志,2004；24(4)：312—316.
[175]施新猷.医用实验动物学,第2版[M].北京：人民卫生出版社,2000：400-401.
[176]叶任高,沈清瑞.肾脏病诊断与治疗学[M].北京：人民卫生出版社,1996：206—207.
[177]陈世件,胡碧容.慢性肾衰竭患者CD62P和CD63水平及灯盏花对其影响的研究.中国中西医结合肾病杂志,2002；3(11)：661-662.
[178]韦芳宁,杨霓芝.血小板膜糖蛋白与慢性肾功能衰竭.实用医学杂志,2009；25(2)：316-317.
[179]热娜古丽·艾则孜,哈木拉提·吾甫尔,金伟.血栓前状态分子标志物的研究进展.新疆医学,2007；37：111-113.
[180]余国忠.P选择素与血小板活化.中国医药导刊,2006；8(2)：108-109.
[181]朱月文.慢性肾功能衰竭患者CD62P表达与肾功能的关系.浙江临床医学,2006；8(6)：597-598.
[182]戴勇,李富荣,贺晓蕾,等.慢性肾功能不全患者外周血血小板P—选择素、L-选择素和细胞间粘附分子-1表达的研究.中国现代医学杂志,2003；13(8)：31-33.
[183]蒋亚平.血小板粘附分子在慢性肾功能衰竭中的变化及意义.河北医学,2005；11(6)：575-577.
[184]韦芳宁,杨霓芝,黄宪章,等.益气活血中药血液透析液对慢性肾功能衰竭患者血小板膜糖蛋白CD62P表达的影响.中国中西医结合杂志,2007；2(2)：106-109.
[185]宋锦叶,李深,孟力强,等.黄芪当归合剂对5／6肾切除大鼠肾组织损伤的治疗作用.北京大学学报：医学版,2009；41(2)：196-202.
[186]万鸿君,彭芳,李艳.慢性肾功能不全患者血清TNF-α水平的变化.临床内科杂志,2005；22(11)：775-776.
[187]唐学飞.肾功能衰竭出血病人血液透析体外循环抗凝新研讨.中医药导报,2006；3(14)：36.
[188]甘晓斌,慢性肾功能衰竭患者TNF-α和CD62P的表达及意义.中外医疗,2008；10：5-6.
[189]FedulovAV, SesTP, Gavrisheva NA, et al. Serum TGF-beta 1 and TNF-alpha levels and cardiac fibrosis in experimental chronic renal failure. Immunol Invest,2005; 34(2):143-52.
[190]杨朝晖,甘华.细胞因子对肾间质纤维化形成的影响.中国现代医学杂志,2004；14(5)：50—53.
[191]周剑锋.BMP7／BMP7R／Smads、TGFβ1与肾纤维化.重庆医学,2006；3(18)：1709-1711.
[192]Zeisberg M,Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverseschronic renal injury. Nat Med,2003； 9:964-968.
[193]马云波.TGF-β与肾小管间质肾炎关系的研究进展.国际泌尿系统杂志,2007；27(4)：537-541.